Healthcare most active stocks: Orexigen Therapeutics (NASDAQ:OREX), Express Scripts Holding (NASDAQ:ESRX), Karyopharm Therapeutics Inc (NASDAQ:KPTI), Novavax (NASDAQ:NVAX), Bristol-Myers Squibb (NYSE:BMY)

According to a statement of Orexigen Therapeutics, Inc. (NASDAQ:OREX), the U.S Food and Drug Administration hasn’t given a green signal to its new drug which helps people in fighting from obesity. One of the spokespersons of the company said,” FDA has delayed its decision on our drug for as much as 3 months. So we will be able to get a final call only after … Continue reading Healthcare most active stocks: Orexigen Therapeutics (NASDAQ:OREX), Express Scripts Holding (NASDAQ:ESRX), Karyopharm Therapeutics Inc (NASDAQ:KPTI), Novavax (NASDAQ:NVAX), Bristol-Myers Squibb (NYSE:BMY)

Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Zogenix, Inc (NASDAQ:ZGNX) CEO Roger Hawley unloaded 25,078 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.10, for a total transaction of $52,663.80. Following the completion of the sale, the chief executive officer now directly owns 1,204,447 shares in the company, valued at approximately $2,529,339. Zogenix, … Continue reading Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) … Continue reading Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co (NYSE:BMY) and Urban Outfitters (URBN) retreated 6.1 percent and 3.6 percent respectively, after brokers lowered their ratings on these stocks. Weaker-than-expected first-quarter results and dismal second-quarter earnings guidance led Wal-Mart Stores (WMT) to drop 2.4 per cent. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -6.12% in last session and finished the day at $48.93. Traded volume was 28.56million shares in the last … Continue reading Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Zacks restated their neutral rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Wednesday. The firm currently has a $52.00 price target on the stock. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.14% in last session and finished the day at $49.52. Traded volume was 8.89million shares in the last session and the average volume of the stock … Continue reading Healthcare Most Active Movers: Bristol-Myers Squibb (NYSE:BMY), Ariad Pharmaceuticals (NASDAQ:ARIA), Avanir Pharmaceuticals (NASDAQ:AVNR), Rexahn Pharmaceuticals (NYSEMKT:RNN)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)